IAVI’s Post

IAVI and our partners UNITAID, Medecins Patent Pool, and Wellcome are proud to announce a new publication providing insight into novel approaches that can expand access to monoclonal antibodies for those in low- and middle- income countries. https://lnkd.in/enVkPsF7

Saturday, July 6, is World Zoonoses Day! On this date in 1885, the first rabies vaccine was administered. This year, IAVI is marking progress toward a vaccine for a globally important zoonotic illness: Lassa fever. A new website feature highlights some recent publications and announcements marking some exciting steps forward: 🔵 An updated Lassa research roadmap in The Lancet co-authored by Swati Gupta, IAVI’s head of emerging infectious diseases. 🔵 The announcement of the start of vaccinations in a Phase 2 clinical trial of IAVI’s Lassa fever vaccine candidate in Liberia. 🔵 A commentary on African leadership in Lassa vaccine development by Dr. Gaudensia Mutua, a medical monitor on our Lassa trials. Read and share the feature to help IAVI and our partners celebrate these developments!👇 #globalhealth #lassafever #vaccineswork #partnerships #outsmartepidemics CEPI (Coalition for Epidemic Preparedness Innovations) | Global Health EDCTP3 | National Institute of Allergy and Infectious Diseases (NIAID) | Viral Hemorrhagic Fever Consortium | Batavia Biosciences

📢 “Many EIDs are being underestimated,” stated Swati Gupta, Ph.D., in a recent interview with Global Health Hub Netherlands. As IAVI’s Vice President and Head of Emerging Infectious Diseases, Gupta is attuned to the public health challenges posed by the global spread of #EIDs — including Lassa fever, Marburg virus, and Sudan Ebolavirus. According to Gupta, these diseases cannot be tackled without addressing broader pandemic preparedness initiatives and healthcare equity concerns. The interview further highlights IAVI’s efforts to promote local capacity strengthening and develop globally accessible vaccines, with the support of the Dutch Ministry of Foreign Affairs and the Dutch Global Health Hub. Read the full article to learn more: https://ow.ly/vrjC50SqtWS

IAVI congratulates our partner PREVAIL in Liberia on starting vaccinations in a Phase 2a clinical trial of IAVI’s Lassa fever vaccine candidate! PREVAIL expects to enroll 204 participants at the JFK Hospital in Monrovia, Montserrado County. This Phase 2a study is the next step of IAVI and CEPI (Coalition for Epidemic Preparedness Innovations)'s Lassa vaccine development partnership, launched in 2018. Importantly, it’s the most advanced clinical trial of a Lassa vaccine to date. Vaccinations are ongoing in Nigeria, and we expect to enroll additional participants in Ghana. Lassa fever is one of the pathogens in the World Health Organization R&D Blueprint list of epidemic threats needing urgent R&D action. No vaccine is available for this viral hemorrhagic illness, and treatment is limited, despite seasonal outbreaks and high case fatality rates. Read more: https://lnkd.in/dFwNeHrf

IAVI and partners in the EDCTP-funded UPTAKE study are proud to share a the first publication from Kenneth R. Katumba. Kenneth is based at MRC/UVRI & LSHTM Uganda Research Unit and one of two UPTAKE PhD candidates enrolled at London School of Hygiene and Tropical Medicine, U. of London. The paper, 'Understanding the contexts in which female sex workers sell sex in Kampala, Uganda: a qualitative study' discusses the value of researchers and implementers in considering the differences in the contexts, challenges, and risks of where women sell sex to design innovative interventions and programs that reach and include all women. 📰 Read it at: https://lnkd.in/e6irR3pE Busara | KAVI Institute of Clinical Research (KAVI-ICR) | Global Health EDCTP3

Join us on our journey as we prepare for IAVI’s first Phase 2b clinical trial. In our latest Meet the Scientist podcast episode, we sat down with Elana Van Brakel, medical director at IAVI in Cape Town, South Africa, to explore IAVI’s engagement in the development of the MTBVAC TB vaccine candidate that is set to enter a Phase 2b clinical trial in adolescents and adults in sub-Saharan Africa later this year. Tune in to this episode to discover how Elana and IAVI’s TB team are preparing for this milestone trial. 🌐🔬 #SciencePodcast #newTBvaccines #YesWeCanEndTB 🔗 https://lnkd.in/eg84JUh5

Stay up to date with IAVI's work across HIV, tuberculosis, and emerging infectious diseases. Sign up for our newsletter or IAVI Report at www.iavi.org/subscribe!

Congratulations to our partners Biofabri and TBVI on their recent partnership announcement with the European Health and Digital Executive Agency, which will accelerate the development of the MTBVAC #tuberculosis #vaccine candidate. Last year, tuberculosis was the world's deadliest infectious disease. Effective new TB vaccines have the potential to save millions of lives, and additional support for their development is wonderful news. https://lnkd.in/ezrJ_ZfC